Abstract
Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The `FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lebowitz, P., Prendergast, G. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17, 1439–1445 (1998). https://doi.org/10.1038/sj.onc.1202175
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202175
Keywords
This article is cited by
-
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Oncogene (2022)
-
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology (2011)
-
5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics
Oncogene (2009)
-
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
Leukemia (2008)
-
Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition
Oncogene (2008)